Drug Trial Radar · NCT07633301
A Study of TAK-360 in Adults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
92
Planned (sponsor's estimate)
Start
Jun 4, 2026
Primary completion
Nov 28, 2027
Study completion Nov 28, 2027
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jun 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Narcolepsy is a sleep disorder that disrupts a person's regular sleep-wake cycle. It causes extreme sleepiness during the day (called excessive daytime sleepiness \[EDS\]), where a person may fall asleep without warning. Narcolepsy Type 1 (NT1) is a form of the condition in which people also have sudden, unexpected muscle weakness while staying conscious (called cataplexy). The main aim of this study is to learn how safe TAK-360 is and how well adults with NT1 tolerate it. Adults who can participate in the study will have to stop taking their existing medicines for NT1 before study treatment starts. Participants may be randomly (by chance, like drawing names from a hat) assigned to get either TAK-360 or placebo during the treatment period. The placebo looks just like TAK-360 but does not have any medicine in it. After the treatment period, participants can be monitored for another 2 weeks. Participants can restart their usual NT1 treatment after study treatment ends. The participants will have to visit the clinic multiple times during this study.
Conditions
- Narcolepsy Type 1
Interventions
TAK-360Drug
TAK-360 tablet
PlaceboDrug
TAK-360 matching placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A, B and C: Number of Participants With at Least One Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 28 weeks
Locations
18 sites in 7 countries. Site status is shown where the registry gives one.
Takeda Site 12
Redwood City, California · Not yet recruiting
Takeda Site 14
Miami, Florida · Recruiting
Takeda Site 13
Cincinnati, Ohio · Recruiting
Takeda Site 2
Macquarie Park, New South Wales, Australia · Not yet recruiting
Takeda Site 4
Beijing, Beijing Municipality, China · Recruiting
Takeda Site 3
Guangzhou, Guangdong, China · Recruiting
Takeda Site 5
Zhengzhou, Henan, China · Recruiting
Takeda Site 7
Paris, France · Not yet recruiting
Takeda Site 6
Herault, Montpelier, France · Not yet recruiting
Takeda Site 8
Bologna, Emilia-Romagna, Italy · Not yet recruiting
Takeda Site 9
Verona, Veneto, Italy · Not yet recruiting
Takeda Site 17
Fukuoka, Fukuoka, Japan · Recruiting
Takeda Site 1
Kumamoto, Kumamoto, Japan · Recruiting
Takeda Site 18
Isahaya-shi, Nagasaki, Japan · Recruiting
Takeda Site 15
Yodogawa-ku, Osaka-shi, Osaka, Japan · Not yet recruiting
Takeda Site 16
Shinjuku-ku, Tokyo, Japan · Recruiting
Takeda Site 11
Barcelona, Spain · Not yet recruiting
Takeda Site 10
Madrid, Spain · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.